Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00663234 · ClinicalTrials.gov registry record · Phase 1
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
A Phase 1 study, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00663234 is a Phase 1 study that was terminated before completion, run by International Maternal Pediatric Adolescent AIDS Clinical Trials Group. The registered enrollment target is 28 participants.
The verdict
NCT00663234, a Phase 1 study, was terminated before completion, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Treatment of HIV with combination antiretroviral regimens frequently results in the suppression of HIV viral load, significant immune recovery, and delayed disease progression. However, treatment with these regimens, particularly protease inhibitors (PIs), has been associated with significant increases in cholesterol and triglycerides in HIV-infected adults and children. The purpose of this study was to evaluate the safety and effectiveness of escalating doses of atorvastatin, a FDA-approved drug which lowers cholesterol and triglyceride levels, in HIV-infected children receiving stable antiretroviral regimens.
Interventions
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-08 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00663234
The ClinicalTrials.gov registry entry for NCT00663234 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atorvastatin is the first listed.
NCT00663234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00663234 about?
NCT00663234 is a clinical study titled "IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia". Treatment of HIV with combination antiretroviral regimens frequently results in the suppression of HIV viral load, significant immune recovery, and delayed disease progression. However, treatment with these regimens, particularly protease inhibitors (PIs), has been associated with significant increa...
What is the current status of trial NCT00663234?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-08. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00663234?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00663234?
This trial is sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.